Safusidenib

Oligodendroglioma

Nuvation Bio Inc.Small moleculePhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 89/ 100

Competitive context

7 Active assets in the Oligodendroglioma cohort.

Asset / Sponsor	Phase	Rating
Nivolumab University of Florida	Phase 2	B
Trebananib National Cancer Institute (NCI)	Phase 2	B
(+)-VINCRISTINE National Cancer Institute (NCI)	Phase 2	B
Irinotecan National Cancer Institute (NCI)	Phase 2	B
Cediranib National Cancer Institute (NCI)	Phase 2	B

View all 25 →

Same molecule, other indications

Safusidenib is also rated in:

glioblastomaDormant

B

Indicative ·

60 / 100

astrocytoma, IDH-mutant, grade 3Dormant

B

Indicative ·

60 / 100

astrocytoma, IDH-mutant, grade 4Dormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.